Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Completed 3Unknown 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 23Myeloid 17Sarcoma 9Gastrointestinal 7Lymphoid 6Tumor-Agnostic 2Other solid neoplasm 2Dermatologic 2Thoracic 1Head & Neck 1CNS 1

Conditions

Neoplasms 2

Interventions

Radiotherapy 9Drug Therapy 9Cisplatin 9Gemcitabine 8Docetaxel 7Carboplatin 7Blood Specimen Collection 7Nivolumab 6Fluorouracil 6Pemetrexed 5Capecitabine 5pembrolizumab 4Surveys and Questionnaires 4Positron Emission Tomography Computed Tomography 4Paclitaxel 4Oxaliplatin 4Exercise 4Everolimus 4Data Collection 4Cetuximab 4indibulin 3icotinib 3Vincristine 3Trastuzumab 3Standard of Care 3Radiosurgery 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Imatinib Mesylate × Tumor-Agnostic × Clear all
NCT02461849 2022-06-15

Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Samsung Medical Center

Phase 2 Unknown
14 enrolled
Tumor-Agnostic

Neoplasms

NCT03381053 2017-12-21

Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation

Shanghai Zhongshan Hospital

Unknown
3,000 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡